Method for obtaining a crystallised foetal bovine serum with agmatine

The crystallization of fetal bovine serum with agmatine addresses storage and contamination issues in existing formulations by enabling room temperature storage and precise dosage, enhancing cellular productivity and reproducibility in cell culture applications.

WO2024246625A1PCT designated stage expired Publication Date: 2024-12-05MOEDANO LARA RAÚL FRANCISCO
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/053443
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-04-08
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current fetal bovine serum formulations require cold chain storage, leading to batch-to-batch variability, contamination risks, and limited reproducibility in cell culture applications, which complicates experimental consistency and safety, especially for human drug and vaccine development.

Method used

A crystallization process that converts fetal bovine serum into a stable, crystallized form using agmatine, allowing for room temperature storage and precise dosage without compromising product integrity, enhancing cellular productivity and reducing contamination risks.

Benefits of technology

The crystallized fetal bovine serum maintains optimal protein expression and cell growth efficiency, eliminating the need for refrigeration and reducing contamination, thereby improving reproducibility and safety in cell culture applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000009_0001
    Figure IMGF000009_0001
  • Figure IMGF000009_0002
    Figure IMGF000009_0002
  • Figure IMGF000010_0001
    Figure IMGF000010_0001
Patent Text Reader

Abstract

The invention relates to a method for obtaining crystallised foetal bovine serum by adding agmatine that, at a specific concentration, acts to increase cell production and increase protein expression per cell. The method further relates to the specific form of reconstitution to liquid indicated in order to use same, without losing the original properties, allowing storage without an ultra-cold chain and reducing the risks of contamination, thereby allowing precise dosing of the amount to be used.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PROCESS FOR OBTAINING CRYSTALLIZED FETAL SERUM

[0002] BOVINE WITH AGMATINE

[0003] FIELD OF INVENTION

[0004] The present invention relates to the field of biotechnology, specifically to a process of crystallization and reconstitution of a supplement for cell culture medium.

[0005] OBJECT OF THE INVENTION

[0006] The object of the invention is a process for obtaining crystallized fetal bovine serum, adding agmatine that was selected by testing several polyamines and finding the one that best acts in increasing cell production and increasing protein expression per cell, obtaining an optimal crystallization efficiency of 98% with respect to a liquid fetal serum; as well as the indicated form of reconstitution to liquid specific for use, without losing the original properties, allowing storage free of ultra-refrigeration chain and reducing the risks of contamination because it allows precise dosage to the amount of use.

[0007] BACKGROUND

[0008] For plant and animal cell culture, there is a constant need to use protein serums that provide the growth nutrients necessary for efficient cell development and the production of desired proteins or viruses. For the effective development of biological products, such as viruses or recombinant proteins, it is important to achieve optimal cell density and enhance protein expression to achieve maximum product yield.

[0009] Generally, known fetal bovine serum formulations require a cold chain for transport and storage. The crystallized fetal bovine serum presented in this invention is an innovative product presented in the form of fine crystals, which is conveniently adjusted with respect to the undesirable proportions of albumin, transientin, mycoplasma and bovine spongiform encephalopathy, making the product safe, particularly for use in pharmaceuticals or vaccines for human use.

[0010] Currently, alternatives have been sought to provide effective culture conditions that significantly reduce contamination from thawing and collecting what is necessary for laboratory use. Our invention arose from the need to offer a process that eliminates these and some other technical problems with serums currently on the market.

[0011] Batch-to-batch variability related to variations in serum component concentrations and their biological activity can ultimately lead to experimental variability and limit inter-laboratory reproducibility, particularly for primary cell culture, expansion, and differentiation, which represents a major cost associated with cell culture. Due to the questionable reproducibility of models based on fetal bovine serum, their use for regulatory purposes is debated. For this reason, serum-supplemented media should be avoided whenever possible, and chemically defined media are preferred (van der Valk, et al., 2018).

[0012] Ideally, they should have enough serum for a complete study. And when they switch to a new bottle, they should make sure that no other reagents have changed and that they have enough old serum stored to test whether any strange results can be attributed to the change. It's easy, for example, to conclude that something is wrong with a protocol for introducing DNA into cells when a new batch of serum has affected division rates. Researchers should also record information provided by suppliers about the serum, including lot numbers (Baker, M, 2016).

[0013] To avoid serum contamination, some researchers are turning to gamma radiation. Several common contaminants, including Mycoplasma, are sensitive to even low levels of radiation. But this requires a balancing act: Radiation also damages growth proteins and bioactive molecules that help cells thrive. Cell culture consultant Raymond Nims of RMC Pharmaceutical Solutions in Longmont, Colorado, advises anyone planning to work with gamma-irradiated serum to first test that the cells are functioning as expected and to remember that even contaminant-free serum cannot prevent infection from other sources (Baker, M, 2016).

[0014] The use of fetal bovine serum-free media reduces animal suffering and can lead to more reproducible in vitro methods, some of which are being developed to replace or reduce animal experiments, contributing to the replacement, reduction and improvement of animal experiments. Therefore, safety, scientific and ethical aspects are incentives to develop and use fetal bovine serum-free media (van der Valk, et al., 2018).

[0015] We have successfully eliminated the cold chain in the use of the final product, making it possible to handle its dosage without contamination and significantly reducing consumer costs by allowing it to be stored at room temperature. We developed a crystallized fetal bovine serum. By classifying, mixing, and treating different fetal bovine bloods, we first obtain a fetal serum that, upon crystallization and dissolution, converts to a liquid. Upon crystallization, we obtain it in solid form, which, when incorporated into a culture medium, provides the desired efficiency and cellular productivity.

[0016] The innovation lies in the product's transformation process, as the only dominant product on the market is the well-known liquid fetal bovine serum. However, through a crystallization process, we have developed this new presentation, which represents a market innovation.

[0017] The fetal bovine serum in crystals related to the present invention is a product that is presented in solid form through fine crystals, which maintain the same properties as the liquid product, without the need to be frozen, with greater efficiency and performance when handling; some of the virtues acquired with this product are: eliminating the cold chain, increasing the preservation of the product on the shelf, being able to store the product at room temperature at no more than 30 ° C, avoiding the need for refrigeration, offering a dosage without contamination without violating the integrity of the product; all of this makes it more efficient in the distribution and marketing process.

[0018] The characterization of crystallized fetal bovine serum on which this invention is based is the process in which the required quantities must be made available based on a table of solutions to prepare the necessary media and by simply regenerating the crystals again in a depyrogenated water solution, fetal bovine serum can be obtained with the same properties as the one already known in liquid form.

[0019] Naturally, fetal bovine serum is an input that comes in liquid form; however, it is a sensitive and delicate product when it comes to handling, since it must be stored at a minimum temperature of -20° C and can only be used once after being thawed, this due to the loss of properties upon thawing. Furthermore, fetal bovine serum formulations on the market require a cold chain for transport. The fetal bovine serum obtained through our crystallization process is an innovative product presented in the form of fine crystals, which reduces the proportions of undesirable substances such as albumin, transerrin, mycoplasma and bovine spongiform encephalopathy virus, making it a safe product, particularly if used in pharmaceuticals or vaccines for human use.With our invention, crystallized fetal bovine serum allows for uniform cell growth and an increase in the yield of desired products, particularly proteins. The specialty of our invention is the use of agmatine, a short-chain polyamine, in the bovine serum crystallization process. This acts synergistically to increase cell growth, specific cell productivity, and final cell density.

[0020] Selected patents from the patent database, specifically from the international classification A 61 of the Human Needs Section, mention the state of the art in section A61K35 / 16, where the patent with the number US2009124011A1 serum production system, describes bovine serum compositions having controlled bovine serum characteristics and methods for producing such compositions from the whole blood of an offspring of a female bovine mammal; this patent describes the control of fetal bovine serum characteristics through production conditions, but does not mention a crystallization process.

[0021] In sections A61D1 / 00 , A61D1 / 08 , A61K35 / 16 ,B01D17 / 00 ,B01D35 / 00 , B01D57 / 00 patent CN101112334A fetal bovine blood serum production technology, refers to a fetal bovine serum and more particularly to a process for producing fetal bovine serum; the invention comprises the collection, separation, filtration and subsequent freezing for storage; this patent does not mention a crystallization process as we mention in our patent; none of them mentions a procedure for the crystallization of fetal bovine serum with agmatine, especially with the specifications as we detail in this invention.

[0022] Interestingly, we have found that fetal bovine serum crystallized using our process is more favorable for protein expression and cell growth rate compared to natural fetal bovine serum, which is considered standardized products with respect to its production.

[0023] DESCRIPTION OF THE INVENTION

[0024] Our invention is described in detail, mentioning its features and how it works, with reference to the steps involved and figures, as well as highlighting the differences with what is already known.

[0025] EXAMPLES Example 1.

[0026] Several analyses were performed to determine the different parameters that the reference fetal bovine serum must meet, such as the amount of protein and albumin, in order to be able to match or improve the product in a different presentation such as the crystallized one:

[0027] The following results were obtained:

[0028] Once these batches of fetal bovine blood were identified, mixtures were made to match the physicochemical characteristics of fetal bovine blood, which were defibrillated and centrifuged at 8,000 rpm. For 30 minutes at 4 °C in a Beckman Coulter centrifuge model Avanti JxN-26, they were ultrafiltered with nitrogen pressure, using Pali Acropack filters of 0.10 microns twice and placed in sterile PETG containers.

[0029] Based on the tests carried out, the most significant batches, which gave mostly satisfactory results, are listed below:

[0030] A mixture was obtained with characteristics similar to the reference fetal bovine serum, checking these analyses with those carried out in a certified laboratory such as LABORATORIOS LEI, where parameters such as protein, albumin, immunoglobulins, endotoxins, osmolarity, hemoglobin and hydrogen potential were checked (laboratory results are attached as annex "A").

[0031] From the second batch with an effective mixture the following was obtained:

[0032] This batch was sent to the Mexican Social Security Institute of the 21st Century, to the immunology area where the same studies were performed, but a cell growth analysis was already available, with HUVEC, RAJI and HTP-1 cells (laboratory results are attached as annex "B").

[0033] For the next batch, the following mix was made:

[0034] The sample was sent again to the Mexican Institute of

[0035] Social Security of the 21st Century, to the Immunology Department, where physical, chemical, and cell growth tests continued. The sample was also taken to the National Polytechnic Institute, to the Biotechnology Department, where a cell culture was performed using HeLa cells (lab results are attached as Appendix "A"). For the next batch, the following mixture was prepared: FBS: Fetal bovine serum.

[0036] SE: Refers to a 40% ethyl solution

[0037] Example 2. Work began on improving the physical properties of the product such as consistency and color, so freeze-drying was considered, which was carried out at the Autonomous University of the State of Hidalgo (UAEH), where the results were not positive in either appearance or physicochemical properties, since they did not reach the properties of conventional fetal bovine serum.

[0038] Example 3. Another batch with significant results is the following:

[0039] Some chemical products were used to eliminate the water and the resulting solid, searching for other polyamines and polyamides, until reaching the expected results, doing small error tests until concluding which was the organic reagent that gave the expected results.

[0040] Example 4. For the following batch, the following mixture was made:

[0041] The same conditions as LOT DQ-297 / 14 - 12-2020 were used again, but in a larger quantity. The previous results were obtained again, but now it was purified with the addition of ethyl alcohol, removing the excess with a water bath, drying them at 30 ° C and irradiating them with ultraviolet light for 30-45 minutes, for sanitization.

[0042] Example 5. For the use of the product, the required quantities are made available based on a dissolution table to prepare the necessary media; by simply regenerating the crystals again in a depyrogenated water solution, fetal bovine serum can be obtained with the same properties as the one already known in liquid form. The table above is based on 48.50 grams per liter of fetal bovine serum crystals, and the solutions are made from this data. The efficiency of our process has allowed the batches of crystallized fetal bovine serum obtained to have consistent amounts of protein.

[0043] Once the fetal bovine serum has been crystallized, the specified quantities must be supplied in diluent solution as shown in the previous table of solutions, to obtain the indicated percentage in the corresponding culture medium, having a 10% solution. This same table shows the equivalence corresponding to the milliliters of liquid fetal bovine serum, as a finished product.

[0044] FOR OBTAINING CRYSTALLIZED BOVINE FETAL SERUM, IT HAS BEEN

[0045] THE FOLLOWING PREFERRED EMBODIMENT OF THE INVENTION HAS BEEN SELECTED:

[0046] They began to search for polyamides and found some aliphatic ones where the literature indicated that they were very easy to polymerize and more so if there were pH changes, so it was decided to continue searching for polyamines now. The literature mentioned that they are friendlier to proteins and if they are of low molecular weight and melting point they were even better, which led to the making of mixtures with aliphatic ones, where different tests were carried out changing the variants of consistency, appearance, color, quantity, manageability, polyamine concentration, alcohol concentration, temperature, dehydration, negative-positive chemical-biological effect and crystallization.

[0047] When starting to work with polyamines, agmatine, spermine and spermidine were found available, where each one was handled with the same variables as the polyamines and doing the same tests of consistency, appearance, color, quantity, manageability, polyamine concentration, ethyl alcohol concentration, temperature, dehydration, negative-positive chemical and biological effect and crystallization, where the best results are those that are put into consideration and that met the positive chemical-biological characteristics.

[0048] I describe in a sufficient and clear manner the steps of the preferred embodiment of our invention, Obtaining Crystallized Fetal Bovine Serum, to put it into practice. 1. The origin of the animal (female bovine) is identified.

[0049] 2. The animal is checked to ensure it meets health requirements; it must have a complete record of illnesses, vaccinations, and food.

[0050] 3. Select the female cattle that meet the following characteristics: a) Up to 7 months of gestation. b) Disease-free. c) Fully vaccinated. d) Nutritionally healthy with a grass-based diet.

[0051] 4. Desensitization is performed using CACHETERO CASH so that the animal can be slaughtered without cruelty.

[0052] 5. The animal is slaughtered by vertically slitting its throat.

[0053] 6. The bovine fetus is drained.

[0054] 7. The fetus is then extracted from the bovine vertically.

[0055] 8. Fetal blood is extracted vertically and must be collected under hygienic conditions in polypropylene bags so that it does not become contaminated and can be processed.

[0056] 9. The blood is checked for any external contaminants. It is examined visually and manually to verify whether the fetal blood was properly cleaned at the time of extraction, whether a clot is beginning to form, and whether the blood's characteristics, such as color and density, are checked.

[0057] 10. Let the blood rest for 5 hours to form a clot, keeping it on ice so that microorganisms do not develop.

[0058] 11. The blood is subjected to mechanical defibrillation to break up all types of clots.

[0059] 12. The blood is subjected to centrifugation to separate the serum at 8,000 rpm, for 30 minutes at 4°C in a Beckman Coulter centrifuge model Avanti JxN-26.

[0060] 13. Decantation is carried out.

[0061] 14. Fetal bovine serum is obtained.

[0062] 15. The serum is placed in oval-shaped homogenization vats with a capacity of 10 to 20 liters where it is homogenized by mechanical means, that is, by circular, horizontal, vertical and vibrational movements.

[0063] 16. Homogeneous serum is obtained.

[0064] 17. The serum is transferred to cylindrical stainless steel containers with an interior slope. The outside is fitted with a pressure gauge to measure the nitrogen delivery pressure, a hermetically sealed lid, and a flexible connection extending from the cylinder to the 10- to 20-liter container. This container must be connected to a nitrogen delivery system for packaging based on the desired dosage.

[0065] 18. The serum is triple filtered using 0.1 micron Pali Acropack filters to remove toxins and unwanted chemicals. 19. Package for distribution under hygienic and completely aseptic conditions.

[0066] 20. Once the serum is packaged, it is irradiated with ultraviolet light for 30-45 minutes to ensure sterilization of the product.

[0067] 21. The serum is frozen at -21° Celsius for storage.

[0068] 22. Pure fetal bovine serum is thawed at room temperature of 8 to 12 degrees Celsius.

[0069] 23. 80 ml of 30% agmatine is added with water obtaining a pH of 6, the mixture corresponds to 600 ml of fetal bovine serum plus 80 ml of 30% agmatine and 100 ml of 40% ethyl solution in water at pH 6.

[0070] 24. Incubate for 2 hours at -5°C.

[0071] 25. Centrifuge at -6 o C at a speed of 8,000 rpm for the separation of solid matter.

[0072] 26. If solids are present after centrifugation, the solids in the sample are discarded.

[0073] 27. A 12.80% solution of 40% ethyl alcohol is added to the compound of fetal bovine serum with agmatine, which helps maintain the properties of Fetal Bovine Serum without affecting its chemical composition.

[0074] 28. It is subjected to centrifugation at 8,000 rpm at a maximum temperature of -5 °C for the separation of solid matter.

[0075] 29. It is progressively subjected to a maximum temperature of 18°C, the time required for the water to be eliminated for dehydration of the product without losing its initial chemical properties. 30. The sample forms fine pink crystals, approximately 1 micron in size.

[0076] 31. Once the crystallized compound is packaged in sterile PETG glycol polyester or glass containers.

[0077] 32. It is irradiated with ultraviolet light for 30-45 minutes to ensure product sanitization.

[0078] 33. Studies of the main parameters are carried out to verify compliance with the quality and asepsis of the product.

[0079] 34. For the use of the product, the required quantities are made available based on a table of solutions to prepare the necessary media; by simply regenerating the crystals again in a depyrogenated water solution, fetal bovine serum can be obtained with the same properties as the one already known in liquid form.

[0080] The quantities for the regeneration of the crystals and their optimal use are in 50 ml of depyrogenated water solution with 0.242 g of crystallized Fetal Bovine Serum; in 100 ml 0.485 g of crystallized Fetal Bovine Serum; in 250 ml 1.2125 g of crystallized Fetal Bovine Serum; in 500 ml 2.425 g of crystallized Fetal Bovine Serum; in 1000 ml 4.85 g of crystallized Fetal Bovine Serum, according to the batch of the test performed.

Claims

CLAIMS Having sufficiently and clearly described our invention, we consider the following clauses to be novel and therefore claim them as our exclusive property:

1. Process for obtaining a crystallized fetal bovine serum with agmatine, which includes the following steps:

1. Identification of the origin of the female bovine.

2. Review of health requirements for female cattle.

3. Selection of the female bovine.

4. Desensitization of the female bovine using the Cachetero Cash technique.

5. Sacrifice of the animal by vertically slitting its throat.

6. Draining the bovine fetus.

7. Extraction of the bovine fetus vertically.

8. Extraction of fetal blood vertically and collected under hygienic conditions in polypropylene bags.

9. Check that the blood does not contain any external contaminants.

10. Blood rest.

11. Mechanical blood defibrination to break up all types of clots.

12. Serum separation by centrifugation.

13. Decantation of fetal bovine serum.

14. Obtaining fetal bovine serum.

15. Placement of fetal bovine serum in homogenization vats.

16. Obtaining homogeneous fetal bovine serum.

17. Placing fetal bovine serum in stainless steel containers.

18. Filtration of fetal bovine serum to remove toxins and unwanted chemical compounds.

19. Packaging of fetal bovine serum for distribution under hygienic conditions and with complete asepsis.

20. Sterilization of fetal bovine serum.

21. Freezing of fetal bovine serum.

22. Thawing of pure fetal bovine serum.

23. Obtaining a mixture consisting of fetal bovine serum with agmatine and water.

24. Incubation of the mixture.

25. Centrifugation of the mixture.

26. Removal of possible solids from the sample after centrifugation.

27. Addition to fetal bovine serum with agmatine, 12.80% ethyl alcohol at 40%, which helps maintain the properties of Fetal Bovine Serum without affecting its chemical composition and to eliminate polyamine residues.

28. Centrifugation for the separation of solid matter.

29. Drying for dehydration of the mixture.

30. Obtaining fine crystals.

31. Packaging of the crystallized compound.

32. Sanitizing the compound with ultraviolet light.

33. Performing tests for quality control.

34. Regeneration of crystals.

2. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 3 the selection of the female bovine is based on the age of up to 7 months of gestation.

3. Process for obtaining a crystallized compound of fetal bovine serum with agmatine, according to claim 1, characterized in that in step 10 the blood is left to rest for 5 hours, keeping it on ice.

4. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 12 the serum is separated by centrifugation at 8,000 rpm for 30 minutes at 4°C in a Beckman Coulter centrifuge, Avanti JxN-26 model.

5. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 15 the vats are made of stainless steel with a capacity of 10 to 20 liters of oval shape where it is homogenized by mechanical means, that is, by circular, horizontal, vertical and vibrational movements.

6. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 17 the serum is transferred to a stainless steel cylinder which must be connected to a nitrogen-pushing system for packaging based on the desired dosage.

7. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 18 a triple filtration with nitrogen push is carried out using Pali Acropack filters of 0.10 microns in double.

8. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 20 the sterilization of the fetal bovine serum with ultraviolet light is for 30-45 minutes.

9. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 21 the storage of the fetal bovine serum is at -21° degrees Celsius.

10. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 22 the thawing of the pure fetal bovine serum is at room temperature of 8 to 12 degrees Celsius.

11. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 23 a mixture is obtained consisting of 600 ml fetal bovine serum plus 80 ml agmatine at 30% and 100 ml of 40% ethyl solution in water at pH 6.

12. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 24 the incubation of the mixture is for 2 hours at -5°C.

13. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 25 the centrifugation of the mixture at -6 o C is at a speed of 8,000 rpm for the separation of solid matter.

14. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 27 ethyl alcohol is added to the compound of fetal bovine serum and agmatine, where the concentration of ethyl alcohol is 40%.

15. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 28 the centrifugation is at 8,000 rpm at a maximum temperature of -5°C for the separation of solid matter.

16. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 29, the drying temperature for dehydration of the compound progressively rises to a maximum temperature of 18 °C to avoid losing the initial chemical properties.

17. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 30 fine pink crystals of a size of 1 micron, not limited to 1 micron, are obtained.

18. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 31 the compound can be packaged in sterile PETG glycol polyester or glass containers.

19. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 32 the sterilization of the compound is with ultraviolet light.

20. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 32 the sterilization time of the compound is 30-45 minutes.

21. Process for obtaining a crystallized fetal bovine serum with agmatine, according to claim 1, characterized in that in step 34, the quantities for the regeneration of the crystals and their use can be 50 ml of depyrogenated water solution with 0.242 grams of crystallized Fetal Bovine Serum; 100 ml 0.485 grams of crystallized Fetal Bovine Serum; 250 ml 1.2125 grams of crystallized Fetal Bovine Serum; 500 ml 2.425 grams of crystallized Fetal Bovine Serum; 1000 ml 4.85 grams of crystallized Fetal Bovine Serum.

22. Crystallized fetal bovine serum with agmatine obtained by the process according to claims 1 to 20.

23. The use of a crystallized fetal bovine serum with agmatine in cell cultures to increase cell production and increase protein expression per cell.

24. The use of a crystallized fetal bovine serum with agmatine in cell cultures according to claim 1, for storage free of ultra-refrigeration chain.

25. The use of a crystallized fetal bovine serum with agmatine in cell cultures according to claim 1, using precise dosage according to the claim 2, for the amount of use, reducing risks of contamination.

Citation Information

Patent Citations

  • Fetal cattle blood serum production technology

    CN101112334A

  • Serum Production System

    US20090124011A1

  • Fetal calf serum for in-vitro cell culture and preparation method thereof

    CN106119183A

  • Method for manually removing corpus luteum, obtaining fetal bovine and collecting fetal bovine serum

    CN107746828A

  • Method for extracting fetal bovine serum

    CN108192855A